<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477126</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 037</org_study_id>
    <nct_id>NCT00477126</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Generic GPO Ritonavir Versus Norvir®</brief_title>
  <official_title>Bioequivalence Study of Generic GPO Ritonavir Versus Norvir® in Thai Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Government Pharmaceutical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish bioequivalence of ritonavir generic capsule, with Norvir® as reference drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be performed to evaluate if the new generic GPO ritonavir product is&#xD;
      bio-equivalent to Norvir and to compare the short-term tolerability and safety profiles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish bioequivalence of generic GPO ritonavir, with Norvir® as the reference drug.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the short-term tolerability and safety profiles of generic ritonavir in healthy male and female volunteers.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>start generic product cross over to reference product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>start reference product cross over to generic product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GPO ritonavir versus Norvir</intervention_name>
    <description>RTV generic compared to reference drugs (Norvir, Abbott)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Healthy male or female 18-45 years old&#xD;
&#xD;
          -  Documented negative test for HIV-1 infection &lt; 1 wk prior to start of study and with&#xD;
             no risk of&#xD;
&#xD;
          -  HIV exposure in the last 6 months&#xD;
&#xD;
          -  For female subjects: documented negative pregnancy test &lt;3 wk prior to start of study,&#xD;
             not breastfeeding&#xD;
&#xD;
          -  BMI 18-25&#xD;
&#xD;
          -  Normal physical examination&#xD;
&#xD;
          -  Normal CBC, BUN, Cr, AST, ALT, Total bilirubin, no evidence of active or chronic HBV&#xD;
             or HCV Infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of sensitivity/idiosyncrasy to the drug or chemically related compounds or&#xD;
             excipients, which may be employed in the study.&#xD;
&#xD;
          -  Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          -  Inability to understand the nature and extent of the study and the procedures&#xD;
             required.&#xD;
&#xD;
          -  Participation in a drug study within 60 days prior to the first dose.&#xD;
&#xD;
          -  Febrile illness within 3 days before the first dose.&#xD;
&#xD;
          -  Use of concomitant medication&#xD;
&#xD;
          -  Smoke cigarettes not more than 10 cigarettes a day.&#xD;
&#xD;
          -  Drink alcohol not more than 2 units a day&#xD;
&#xD;
          -  Discontinue smoking and alcohol for at least 1 month before enrollment.&#xD;
&#xD;
          -  Take other medication regularly&#xD;
&#xD;
          -  Involvement in any drug addiction&#xD;
&#xD;
          -  Heart disease, hypertension, liver disease, kidney disease, GI disease, allergic&#xD;
             disease or other diseases which may interfere with the PK of study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiat Ruxrungtham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>May 20, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>April 3, 2012</last_update_submitted>
  <last_update_submitted_qc>April 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2012</last_update_posted>
  <responsible_party>
    <name_title>Kiat Ruxrungtham</name_title>
    <organization>HIV-NAT</organization>
  </responsible_party>
  <keyword>ritonavir generic capsule</keyword>
  <keyword>Norvir®</keyword>
  <keyword>Thailand</keyword>
  <keyword>Determine bioequivalence between Norvir and GPO ritonavir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

